# DESCRIPTION

## FIELD OF THE INVENTION

- define invention scope

## BACKGROUND OF THE INVENTION

- motivate α4 integrin antagonists
- limitations of existing antagonists

## SUMMARY OF THE INVENTION

- summarize invention

## DETAILED DESCRIPTION OF THE INVENTION

- define terms for nomenclature purposes
- describe alkyl, alkenyl, and alkynyl structures
- describe heteroalkyl, heteroalkenyl, and heteroalkynyl structures
- describe haloalkyl, haloalkenyl, and haloalkynyl structures
- describe cycloalkyl and cycloalkene structures
- describe heterocycle and aryl structures
- describe acyl and nucleic acid structures
- define expression vector, host cells, gene, and isolated or purified biomolecules
- describe ester prodrugs
- describe pharmaceutically acceptable salts
- outline embodiments of the invention
- describe pharmaceutical compositions and methods of treatment
- discuss stereochemistry and polymorphism of compounds
- summarize therapeutic applications of the invention

### Pharmaceutical Formulation and Administration:

- formulate active ingredients in pharmaceutically acceptable formulations
- prepare pharmaceutical compositions with suitable carriers or excipients
- determine toxicity and therapeutic efficacy of compounds
- administer therapeutically effective amounts of active ingredients

## EXAMPLES

### Experimental Procedures

- describe cell lines and culture conditions
- outline reagents and their sources
- detail generation of recombinant proteins
- explain ELISA assay procedure

### Example 1

- describe high-throughput screening process

### Example 2

- analyze compound 6-B345TTQ's inhibitory effect on α4-integrin and leupaxin interaction

### Example 3

- investigate compound 6-B345TTQ's effect on α4-mediated cell migration and spreading

### Example 4

- test compound 6-B345TTQ's effect on leukocyte recruitment in vivo

### Example 5

- explore integrin α4β1 signaling in lymphatic endothelial cells

## Equivalents

- disclaim limitations of invention

